BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ:AKRX) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for Akorn’s Abbreviated New Drug Application (ANDA) for Calcitriol Injection, 1 mcg/mL and 2 mcg/mL.
